Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2020’, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH).
  • It reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • The report reviews key players involved Non-Alcoholic Steatohepatitis (NASH) therapeutics and enlists all their major and minor projects.
  • The report assesses Non-Alcoholic Steatohepatitis (NASH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The report summarizes all the dormant and discontinued pipeline projects.
  • The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH).

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

89bio Ltd

ABIONYX Pharma SA

Abivax SA

Acquist Therapeutics

AdAlta Ltd

Affinicon ApS

Afimmune Biopharma Ltd

Akero Therapeutics Inc

Albireo Pharma Inc

Aldeyra Therapeutics Inc

Algernon Pharmaceuticals Inc

Aligos Therapeutics Inc

Allergan Plc

Allysta Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Altavant Sciences Inc

Alteogen Inc

Altimmune Inc

Amgen Inc

Angion Biomedica Corp

AptaBio Therapeutics Inc

Aptamer Sciences Inc

AptamiR Therapeutics Inc

Araim Pharmaceuticals Inc

Arcturus Therapeutics Ltd

Arkay Therapeutics LLC

Arrowhead Pharmaceuticals Inc

ARTham Therapeutics Inc

Ascletis Inc

Asdera

Assembly Biosciences Inc

AstraZeneca Plc

Auransa Inc

Avaliv Therapeutics Inc

Axcella Health Inc

BBN Cardio Therapeutics

BerGenBio ASA

Betagenon AB

Bioio LLC

Bird Rock Bio Inc

Blade Therapeutics Inc

BLR Bio LLC

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Buto Biopharma Inc

Cadila Healthcare Ltd

Califia Bio Inc

Can-Fite BioPharma Ltd

Carmot Therapeutics Inc

CellCure

Centaurus Therapeutics Inc

ChemoCentryx Inc

ChemomAb Ltd

Chia Tai Tianqing Pharmaceutical Group Co Ltd.

China NT Pharma Group Co Ltd

Cirius Therapeutics Inc

CohBar Inc

Coherus BioSciences Inc

ConSynance Therapeutics Inc

Continuum Biosciences Inc

Corbus Pharmaceuticals Inc

Corcept Therapeutics Inc

Curadim Pharma Co Ltd

Cyclerion Therapeutics Inc

Cytodyn Inc

D&D Pharmatech Co Ltd

Daiichi Sankyo Co Ltd

Dicerna Pharmaceuticals Inc

Dr. Falk Pharma GmbH

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

EncuraGen Inc

Engitix Ltd

Enleofen Bio Pte Ltd

Enyo Pharma SA

Enzychem Lifesciences Corp

Epitracker Inc

Esperion Therapeutics Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Fochon Pharmaceutical Ltd

Forma Therapeutics Inc

Future Medicine Co Ltd

Galectin Therapeutics Inc

Galecto Biotech AB

Galmed Pharmaceuticals Ltd

Gemphire Therapeutics Inc

Gencia LLC

General Regeneratives Shanghai Ltd

Genfit SA

GenKyoTex SA

GI Innovation Co Ltd

Gilead Sciences Inc

Gmax Biopharm Ltd

Guangdong East Sunshine Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

H. Lundbeck AS

Hana Pharm Co Ltd

Hanmi Pharmaceuticals Co Ltd

HemoShear Therapeutics LLC

Hepagene Therapeutics Shanghai Inc

Hepion Pharmaceuticals

Heprotech Inc

Hinova Pharmaceuticals Inc

HotSpot Therapeutics Inc

Imago Pharmaceuticals Inc

Immupharma Plc

Immuron Ltd

Indalo Therapeutics Inc

Inmune Bio Inc

Innovate Biopharmacueticals Inc

Innovimmune Biotherapeutics Inc

Inorbit Therapeutics AB

Integral Molecular Inc

Intercept Pharmaceuticals Inc

INVENT Pharmaceuticals Inc

InventisBio Inc

Inventiva

Ionis Pharmaceuticals Inc

J2H Biotech

Jecure Therapeutics Inc

Jiangsu Atom Bioscience and Pharmaceutical Co Ltd

Joyce Biotech Corp

KinDex Pharmaceuticals Inc

Kinomedica Pty Ltd

Kirrhos Pharmaceuticals LLC

KoBioLabs Inc

Korea United Pharm Inc

Kowa Co Ltd

Krisani Bio Sciences Pvt Ltd

Kyorin Pharmaceutical Co Ltd

Laekna Therapeutics Shanghai Co Ltd

LG Chem Ltd

LifeMax Laboratories Inc

Liminal BioSciences Inc

Lin Bioscience Inc

Lipidio Pharmaceuticals Inc

Lipocine Inc

LISCure Biosciences Co Ltd

Lynkogen Inc

Macrophage Therapeutics Inc

Madrigal Pharmaceuticals Inc

Mallinckrodt Plc

Max Biopharma Inc

Melior Pharmaceuticals I Inc

Merck & Co Inc

Metabolic Solutions Development Company LLC

Metabolys SAS

Metacrine Inc

MetiMedi Pharmaceuticals Co Ltd

Micelle BioPharma Inc

Mina Therapeutics Ltd

Mitotherapeutix LLC

Mitsubishi Tanabe Pharma Corp

Morphic Holding Inc

Mperia Therapeutics Inc

MYR GmbH

Naia Ltd

Nanjing Sanhome Pharmaceutical Co Ltd

Nanjing Transthera Biosciences Co Ltd

NeuroVive Pharmaceutical AB

Nexel Co Ltd

NGM Biopharmaceuticals Inc

Nippon Chemiphar Co Ltd

Nivarta Inc

NorthSea Therapeutics BV

Novartis AG

Novo Nordisk AS

NuSirt Biopharma Inc

Oasis Pharmaceuticals LLC

Oramed Pharmaceuticals Inc

Osteoneurogen Inc

Palo BioFarma SL

Pattern Therapeutics

PegBio Co Ltd

Pfizer Inc

pH Pharma Co Ltd

Pharmaxis Ltd

Phenex Pharmaceuticals AG

Pliant Therapeutics Inc

Poxel SA

Promethera Biosciences SA

Protalix BioTherapeutics Inc

Proterris Inc

PTC Therapeutics Inc

RadBio

Redx Pharma Plc

Regenasome Pty Ltd

Regulus Therapeutics Inc

reMYND NV

Revive Therapeutics Ltd

Rhamnopharma Inc

Sagimet Biosciences

Saje Pharma LLC

Salix Pharmaceuticals Ltd

Sanofi

ScandiCure AB

Sciwind Biosciences Co Ltd

Scohia Pharma Inc

Seal Rock Therapeutics Inc

Seres Therapeutics Inc

SFA Therapeutics LLC

Shanghai Anruite Biological Medicine Technology Co Ltd

Shenzhen HighTide Biopharmaceutical Ltd

Shionogi & Co Ltd

Sihuan Pharmaceutical Holdings Group Ltd

Sinew Pharma Inc

Sirnaomics Inc

SparkBioPharma Inc

SteroTherapeutics LLC

Suzhou Zelgen Biopharmaceutical Co Ltd

Sveikatal Inc

Synlogic Inc

T3D Therapeutics Inc

TaiwanJ Pharmaceuticals Co Ltd

Terns Pharmaceuticals Inc

TES Pharma SRL

Theratechnologies Inc

Thetis Pharmaceuticals LLC

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

TreeFrog Therapeutics SAS

Valin Technologies Ltd

Vascular Biogenics Ltd

Vectus Biosystems Ltd

Venenum Biodesign LLC

Verlyx Pharma Inc

Vidasym Inc

Viking Therapeutics Inc

Visionary Pharmaceuticals Inc

Vivus Inc

Wave Life Sciences Ltd

Xenexus Pharmaceuticals Pty Ltd

XORTX Therapeutics Inc

YD Life Science Co

Yuhan Corp

Zafgen Inc

Zebra Discovery Ltd

Zhejiang Doer Biologics Corp

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Non-Alcoholic Steatohepatitis (NASH) Overview

Non-Alcoholic Steatohepatitis (NASH) Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) Therapeutics Assessment

Non-Alcoholic Steatohepatitis (NASH) Companies Involved in Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) Drug Profiles

Non-Alcoholic Steatohepatitis (NASH) Dormant Projects

Non-Alcoholic Steatohepatitis (NASH) Discontinued Products

Non-Alcoholic Steatohepatitis (NASH) Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by 89bio Ltd, H1 2020

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ABIONYX Pharma SA, H1 2020

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Abivax SA, H1 2020

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Acquist Therapeutics, H1 2020

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AdAlta Ltd, H1 2020

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Affinicon ApS, H1 2020

List of Figures

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports